These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35669767)

  • 1. An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19.
    Soleimanian S; Alyasin S; Sepahi N; Ghahramani Z; Kanannejad Z; Yaghobi R; Karimi MH
    Front Immunol; 2022; 13():884879. PubMed ID: 35669767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Bobrovitz N; Ware H; Ma X; Li Z; Hosseini R; Cao C; Selemon A; Whelan M; Premji Z; Issa H; Cheng B; Abu Raddad LJ; Buckeridge DL; Van Kerkhove MD; Piechotta V; Higdon MM; Wilder-Smith A; Bergeri I; Feikin DR; Arora RK; Patel MK; Subissi L
    Lancet Infect Dis; 2023 May; 23(5):556-567. PubMed ID: 36681084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on host immunity correlates and prospects of re-infection in COVID-19.
    Negi N; Maurya SP; Singh R; Das BK
    Int Rev Immunol; 2022; 41(4):367-392. PubMed ID: 34961403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
    Egri N; Calderón H; Martinez R; Vazquez M; Gómez-Caverzaschi V; Pascal M; Araújo O; Juan M; González-Navarro EA; Hernández-Rodríguez J
    Front Immunol; 2023; 14():1146841. PubMed ID: 37180097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses.
    Torresi J; Edeling MA; Nolan T; Godfrey DI
    Front Immunol; 2022; 13():914167. PubMed ID: 35911696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
    Pons S; Uhel F; Frapy E; Sérémé Y; Zafrani L; Aschard H; Skurnik D
    Stem Cell Rev Rep; 2023 Apr; 19(3):585-600. PubMed ID: 36422774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural immune response and protection from SARS-CoV-2 reinfection.
    Margiotti K; Fabiani M; Mesoraca A; Giorlandino C
    Acta Virol; 2021; 65(4):333-338. PubMed ID: 34796710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.
    Cromer D; Juno JA; Khoury D; Reynaldi A; Wheatley AK; Kent SJ; Davenport MP
    Nat Rev Immunol; 2021 Jun; 21(6):395-404. PubMed ID: 33927374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study.
    Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
    Clin Infect Dis; 2022 Aug; 75(1):e545-e551. PubMed ID: 35380632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
    Milne G; Hames T; Scotton C; Gent N; Johnsen A; Anderson RM; Ward T
    Lancet Respir Med; 2021 Dec; 9(12):1450-1466. PubMed ID: 34688434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
    Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARIS and SPARTA: Finding the Achilles' Heel of SARS-CoV-2.
    Simon V; Kota V; Bloomquist RF; Hanley HB; Forgacs D; Pahwa S; Pallikkuth S; Miller LG; Schaenman J; Yeaman MR; Manthei D; Wolf J; Gaur AH; Estepp JH; Srivastava K; Carreño JM; Cuevas F; ; Ellebedy AH; Gordon A; Valdez R; Cobey S; Reed EF; Kolhe R; Thomas PG; Schultz-Cherry S; Ross TM; Krammer F
    mSphere; 2022 Jun; 7(3):e0017922. PubMed ID: 35586986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
    Hammerman A; Sergienko R; Friger M; Beckenstein T; Peretz A; Netzer D; Yaron S; Arbel R
    N Engl J Med; 2022 Mar; 386(13):1221-1229. PubMed ID: 35172072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
    Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
    Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.